Kura Oncology Inc

NASDAQ KURA

Data sourced from

and

Download Data

Kura Oncology Inc Cash Return on Assets (CROA) 2 year CAGR for the Trailing 12 Months (TTM) ending March 31, 2024: 32.76%

Kura Oncology Inc Cash Return on Assets (CROA) 2 year CAGR is 32.76% for the Trailing 12 Months (TTM) ending March 31, 2024, a 38.72% change year over year. The cash return on assets ratio measures the profitability of a company's total assets based on its operating cash flow. It is calculated by dividing operating cash flow by total assets. This ratio indicates the company's ability to generate cash flow relative to its asset base. A higher ratio suggests more efficient utilization of assets in generating cash flow. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Kura Oncology Inc Cash Return on Assets (CROA) for the Trailing 12 Months (TTM) ending March 31, 2023 was -0.06, a -26.73% change year over year.
Kura Oncology Inc Cash Return on Assets (CROA) for the Trailing 12 Months (TTM) ending March 31, 2022 was -0.05, a -20.58% change year over year.
Kura Oncology Inc Cash Return on Assets (CROA) for the Trailing 12 Months (TTM) ending March 31, 2021 was -0.04, a 32.84% change year over year.
Kura Oncology Inc Cash Return on Assets (CROA) for the Trailing 12 Months (TTM) ending March 31, 2020 was -0.06, a 18.98% change year over year.

NASDAQ: KURA

Kura Oncology Inc

CEO	Dr. Troy Edward Wilson J.D., Ph.D.
IPO Date	Sept. 22, 2015
Location	United States
Headquarters	12730 High Bluff Drive, San Diego, CA, United States, 92130
Employees	142
Sector	Healthcare
Industry	Biotechnology

Description

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Key trends